Shi Ce, Liu Chunli, Liu Jinyan, Wang Ying, Li Jian, Xiang Mingjie
Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
Mycopathologia. 2015 Oct;180(3-4):203-7. doi: 10.1007/s11046-015-9899-9. Epub 2015 May 15.
The rate of Candida spp. infection is increasing, and resistance to azole antifungals is becoming increasingly common. Therefore, there is a need for discovery of new antifungal agents and for development of new modes of treatment using existing agents. In this in vitro study, the antifungal activity of two new imidazole derivatives was tested against a set of 20 Candida isolates, which included five different species. Treatment was carried out with the compound alone and in combination with fluconazole. Overall, we found that one of the new compounds, 31, was similar to fluconazole (FLC) in its efficacy against the Candida isolates and that compound 42 was superior to FLC. Furthermore, when combined with FLC, both compounds showed synergistic effects against 17 of the 20 tested isolates. No antagonistic interactions were observed. This study shows that our two new imidazole-derived compounds have good potential as general treatments for Candida infection and as a means to improve the current treatments with FLC.
念珠菌属感染率正在上升,对唑类抗真菌药的耐药性也日益普遍。因此,需要发现新的抗真菌药物,并开发使用现有药物的新治疗模式。在这项体外研究中,测试了两种新型咪唑衍生物对一组20株念珠菌分离株的抗真菌活性,这些分离株包括五个不同的物种。分别使用化合物单独以及与氟康唑联合进行治疗。总体而言,我们发现其中一种新化合物31对念珠菌分离株的疗效与氟康唑(FLC)相似,化合物42优于FLC。此外,与FLC联合使用时,两种化合物对20株测试分离株中的17株均显示出协同作用。未观察到拮抗相互作用。这项研究表明,我们的两种新型咪唑衍生化合物作为念珠菌感染的常规治疗方法以及改善目前FLC治疗效果的手段具有良好的潜力。